Wan Bikang Pill In The Treatment Of Ankylosing Spondylitis Kidney Deficiency And Damp Heat Syndrome To Observe The Clinical Efficacy

Objective: To observe the clinical curative effect and adverse reaction of WanBikang pill in the treatment of ankylosing spondylitis kidney deficiency and dampheat syndrome, kidney, expelling wind and removing dampness heat clearing andclarify the prescription and treatment of ankylosing spondylitis, and provide atheoretical basis for the kidney, expelling wind and dampness heat treatment ofankylosing spondylitis.Methods: According to the random, parallel control, single blind clinical trialprinciple, in the diagnosis of60cases with AS, and patients with kidney deficiencyand damp heat syndrome of TCM syndrome differentiation standard.60patients wererandomly divided into two groups,30cases in test group, the Wan Bikang pill+Lomoxicam dispersible tablets+Sulfasalazine Enteric-coated Tablets oral therapy;the control group of30cases, with Lomoxicam dispersible tablets+SulfasalazineEnteric-coated Tablets oral therapy, treatment for1month. The overall evaluation ofTCM Syndromes of two groups of patients, patients with integral (PGA) score, spinalpain score, Bath Ankylosing Spondylitis Functional Index (BASFI) score, morningstiffness duration and extent of laboratory examination score, erythrocytesedimentation rate (ESR), C-reactive protein (CRP), platelet (PLT) index observationindex, after the end of treatment to determine treatment.Results:①After the treatment of experimental group was2cases, theobservation of28cases; the control group fall off in5cases, the observation of25cases. Two groups of shedding no difference in Statistics (P>0.05).②Comparison ofthe efficacy of TCM, the test group, the effective cases were9cases,15cases, thetotal efficiency of85.71%; control group, markedly effective, effective cases were3cases,13cases, the total effective rate was64%, the two groups were no clinicalremission cases1months. There is significant difference by statistical test (P<0.05), the test group was better than control group.③Comparison of effect of ASAS20, thetest group reached the standard of ASAS20for20cases, efficiency of71.43%; controlgroup reached the standard of ASAS20for11cases, efficiency of44%. There issignificant difference by statistics (P<0.05), the test group was better than controlgroup.④In the clinical observation indexes, were compared before and after treatmentin the experimental group: PGA, spinal pain, stiffness and laboratory indexes of ESR,CRP, PLT, statistical analysis are significantly different (P<0.05), obvious differencein BASFI before and after treatment without (P>0.05); control group only in thespinal pain has a significant the difference (P<0.05), there was no significance thanobserved (P>0.05). Comparison between groups: experimental group after treatmentin the PGA, stiff and CRP is significantly better than the control group (P>0.05),while in spinal pain, BASFI, ESR and PLT has no significant difference between thetwo groups (P>0.05).⑤No significant adverse events occurred in two patients duringthe treatment, and adverse reaction after treatment showed no significant difference (P>0.05).Conclusion: Wan Bikang pill combined with western medicine in the treatmentof AS is helpful to improve the clinical efficacy, exact in inflammatory diseaseactivity index control efficacy, more significant effect in improving the stiffness andother symptoms, and the study found no significant adverse reactions and side effects.